Cargando…

Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma

IMPORTANCE: Refining eligibility guidelines may identify more appropriate patients to undergo useful medical procedures. OBJECTIVE: To improve cost-effectiveness in selecting patients with melanoma for sentinel lymph node biopsy (SLNB). DESIGN, SETTING, AND PARTICIPANTS: This hybrid prognostic study...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, James R., Lo, Serigne N., Nosrati, Mehdi, Stretch, Jonathan R., Spillane, Andrew J., Saw, Robyn P. M., Shannon, Kerwin F., Nieweg, Omgo E., Ch’ng, Sydney, Kim, Kevin B., Leong, Stanley P., Thompson, John F., Scolyer, Richard A., Kashani-Sabet, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116363/
https://www.ncbi.nlm.nih.gov/pubmed/37074717
http://dx.doi.org/10.1001/jamanetworkopen.2023.6356
_version_ 1785028407774412800
author Miller, James R.
Lo, Serigne N.
Nosrati, Mehdi
Stretch, Jonathan R.
Spillane, Andrew J.
Saw, Robyn P. M.
Shannon, Kerwin F.
Nieweg, Omgo E.
Ch’ng, Sydney
Kim, Kevin B.
Leong, Stanley P.
Thompson, John F.
Scolyer, Richard A.
Kashani-Sabet, Mohammed
author_facet Miller, James R.
Lo, Serigne N.
Nosrati, Mehdi
Stretch, Jonathan R.
Spillane, Andrew J.
Saw, Robyn P. M.
Shannon, Kerwin F.
Nieweg, Omgo E.
Ch’ng, Sydney
Kim, Kevin B.
Leong, Stanley P.
Thompson, John F.
Scolyer, Richard A.
Kashani-Sabet, Mohammed
author_sort Miller, James R.
collection PubMed
description IMPORTANCE: Refining eligibility guidelines may identify more appropriate patients to undergo useful medical procedures. OBJECTIVE: To improve cost-effectiveness in selecting patients with melanoma for sentinel lymph node biopsy (SLNB). DESIGN, SETTING, AND PARTICIPANTS: This hybrid prognostic study/decision analytical model was conducted among patients with melanoma who were eligible for SLNB at 2 melanoma centers from Australia and the US from 2000 to 2014. Participants consisted of 2 cohorts of patients with melanoma undergoing SLNB and a cohort of eligible patients without SLNB. Individualized probabilities of SLNB positivity generated by a patient-centered methodology (PCM) were compared with those generated by conventional multiple logistic regression analysis investigating 12 prognostic factors. Prognostic accuracy was assessed by the area under the receiver operating characteristic curve (AUROC) for each methodology and by matched-pair analyses. INTERVENTIONS: Triaging appropriate patients to undergo SLNB. MAIN OUTCOMES AND MEASURES: Total number of SLNBs performed (giving total cost) vs number of SLNB-positive outcomes (a measure of effectiveness) was evaluated. Improved cost-effectiveness through judicious patient selection was interpreted as increased numbers of SLNB-positive outcomes achieved, decreased numbers of SLNBs performed, or both outcomes simultaneously. RESULTS: Among 7331 patients with melanoma, SLNB outcomes were assessed in 3640 Australian patients (2212 males [60.8%]; 2447 aged >50 years [67.2%]) and 1342 US patients (774 males [57.7%]; 885 aged >50 years [66.0%]); 2349 patients eligible for SLNB who did not undergo the procedure were included in the simulation. PCM-generated probabilities achieved an AUROC of 0.803 in predicting SLNB positivity in the Australian cohort and 0.826 in the US cohort, higher than corresponding AUROCs generated by conventional logistic regression analysis. In simulation, adopting many SLNB-positive probabilities as minimally acceptable patient-selection criteria resulted in fewer procedures performed or increased the expected numbers of positive SLNBs. A minimally acceptable PCM-generated probability of 8.7% elicited the same number of SLNBs as historically performed (3640 SLNBs), with 1066 positive SLNBs (29.3%), constituting an improvement of 287 additional positive SLNBs compared with 779 actual positive SLNBs (36.8% improvement). In contrast, adopting a 23.7% PCM-generated minimum cutoff probability resulted in performing 1825 SLNBs, or 1815 fewer SLNBs than the actual experience (49.9%). It resulted in the same expected number of positive results (779 SLNBs), for a 42.7% positivity rate. CONCLUSIONS AND RELEVANCE: This prognostic study/decision analytical model found that the PCM approach outperformed conventional multiple logistic regression analysis in predicting which patients would have positive results on SLNB. These findings suggest that systematically producing and exploiting more accurate SLNB-positivity probabilities could improve the selection of patients with melanoma for SLNB compared with using established guidelines, thus improving the cost-effectiveness of the selection process. Eligibility guidelines to undergo SLNB should include a context-tailored minimum cutoff probability.
format Online
Article
Text
id pubmed-10116363
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-101163632023-04-21 Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma Miller, James R. Lo, Serigne N. Nosrati, Mehdi Stretch, Jonathan R. Spillane, Andrew J. Saw, Robyn P. M. Shannon, Kerwin F. Nieweg, Omgo E. Ch’ng, Sydney Kim, Kevin B. Leong, Stanley P. Thompson, John F. Scolyer, Richard A. Kashani-Sabet, Mohammed JAMA Netw Open Original Investigation IMPORTANCE: Refining eligibility guidelines may identify more appropriate patients to undergo useful medical procedures. OBJECTIVE: To improve cost-effectiveness in selecting patients with melanoma for sentinel lymph node biopsy (SLNB). DESIGN, SETTING, AND PARTICIPANTS: This hybrid prognostic study/decision analytical model was conducted among patients with melanoma who were eligible for SLNB at 2 melanoma centers from Australia and the US from 2000 to 2014. Participants consisted of 2 cohorts of patients with melanoma undergoing SLNB and a cohort of eligible patients without SLNB. Individualized probabilities of SLNB positivity generated by a patient-centered methodology (PCM) were compared with those generated by conventional multiple logistic regression analysis investigating 12 prognostic factors. Prognostic accuracy was assessed by the area under the receiver operating characteristic curve (AUROC) for each methodology and by matched-pair analyses. INTERVENTIONS: Triaging appropriate patients to undergo SLNB. MAIN OUTCOMES AND MEASURES: Total number of SLNBs performed (giving total cost) vs number of SLNB-positive outcomes (a measure of effectiveness) was evaluated. Improved cost-effectiveness through judicious patient selection was interpreted as increased numbers of SLNB-positive outcomes achieved, decreased numbers of SLNBs performed, or both outcomes simultaneously. RESULTS: Among 7331 patients with melanoma, SLNB outcomes were assessed in 3640 Australian patients (2212 males [60.8%]; 2447 aged >50 years [67.2%]) and 1342 US patients (774 males [57.7%]; 885 aged >50 years [66.0%]); 2349 patients eligible for SLNB who did not undergo the procedure were included in the simulation. PCM-generated probabilities achieved an AUROC of 0.803 in predicting SLNB positivity in the Australian cohort and 0.826 in the US cohort, higher than corresponding AUROCs generated by conventional logistic regression analysis. In simulation, adopting many SLNB-positive probabilities as minimally acceptable patient-selection criteria resulted in fewer procedures performed or increased the expected numbers of positive SLNBs. A minimally acceptable PCM-generated probability of 8.7% elicited the same number of SLNBs as historically performed (3640 SLNBs), with 1066 positive SLNBs (29.3%), constituting an improvement of 287 additional positive SLNBs compared with 779 actual positive SLNBs (36.8% improvement). In contrast, adopting a 23.7% PCM-generated minimum cutoff probability resulted in performing 1825 SLNBs, or 1815 fewer SLNBs than the actual experience (49.9%). It resulted in the same expected number of positive results (779 SLNBs), for a 42.7% positivity rate. CONCLUSIONS AND RELEVANCE: This prognostic study/decision analytical model found that the PCM approach outperformed conventional multiple logistic regression analysis in predicting which patients would have positive results on SLNB. These findings suggest that systematically producing and exploiting more accurate SLNB-positivity probabilities could improve the selection of patients with melanoma for SLNB compared with using established guidelines, thus improving the cost-effectiveness of the selection process. Eligibility guidelines to undergo SLNB should include a context-tailored minimum cutoff probability. American Medical Association 2023-04-19 /pmc/articles/PMC10116363/ /pubmed/37074717 http://dx.doi.org/10.1001/jamanetworkopen.2023.6356 Text en Copyright 2023 Miller JR III et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Miller, James R.
Lo, Serigne N.
Nosrati, Mehdi
Stretch, Jonathan R.
Spillane, Andrew J.
Saw, Robyn P. M.
Shannon, Kerwin F.
Nieweg, Omgo E.
Ch’ng, Sydney
Kim, Kevin B.
Leong, Stanley P.
Thompson, John F.
Scolyer, Richard A.
Kashani-Sabet, Mohammed
Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
title Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
title_full Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
title_fullStr Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
title_full_unstemmed Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
title_short Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
title_sort improving selection for sentinel lymph node biopsy among patients with melanoma
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116363/
https://www.ncbi.nlm.nih.gov/pubmed/37074717
http://dx.doi.org/10.1001/jamanetworkopen.2023.6356
work_keys_str_mv AT millerjamesr improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT loserignen improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT nosratimehdi improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT stretchjonathanr improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT spillaneandrewj improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT sawrobynpm improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT shannonkerwinf improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT niewegomgoe improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT chngsydney improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT kimkevinb improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT leongstanleyp improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT thompsonjohnf improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT scolyerricharda improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma
AT kashanisabetmohammed improvingselectionforsentinellymphnodebiopsyamongpatientswithmelanoma